Loading...
•
Sep 28, 2024
USANA Q3 2024 Earnings Report
USANA's Q3 2024 financial performance reflected continued top line headwinds across key markets.
Key Takeaways
USANA Health Sciences reported a decrease in net sales and diluted EPS for the third quarter of 2024 compared to the same period in 2023. Net sales were $200 million, and diluted EPS was $0.56. The company has updated its fiscal year 2024 outlook to approximately $850 million in net sales and $2.45 in diluted EPS.
Third quarter net sales were $200 million, a decrease compared to $213 million in Q3 2023.
Third quarter diluted EPS was $0.56, down from $0.59 in Q3 2023.
The company generated $30 million in operating cash flow during the third quarter.
USANA ended the quarter with $365 million in cash and cash equivalents and remained debt-free.
Revenue by Segment
Revenue by Geographic Location
Forward Guidance
The Company is updating its net sales and earnings per share outlook for fiscal year 2024, as follows: Consolidated Net Sales $850 million and Diluted EPS $2.45.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...